Tumors harboring DDR2 mutations could be more sensitive to SFK inhibitors, as HNSCC cell lines with endogenous and engineered DDR2 mutations are more sensitive to the SFK inhibitor dasatinib than those with wild-type DDR2 [64]. This evidence concerns the gene DDR2 and head and neck squamous cell carcinoma.